NCT04767906View on ClinicalTrials.gov

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Cabozantinib

The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.

Trial Locations (5)

13353

Charite Universitätsmedizin, Campus Virchow Klinikum, Klinik für Hepatologie/Gastroenterologie, Berlin

68167

Universitätsklinikum Mannheim, Mannheim

01307

Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden

04103

MVZ Mitte/MVZ Delitzsch GmbH, Leipzig

University Hospital Leipzig, Leipzig

All Listed Sponsors
lead

University of Leipzig

OTHER

NCT04767906 - Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors | Biotech Hunter | Biotech Hunter